Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35098620/
In most patients, the 3-month discontinuation of anti-CGRP mAbs resulted in progressive migraine deterioration that was rapidly reverted by retreatment. However, one-fourth of patients, who reported better quality of life...
Conclusions: In most patients, the 3-month discontinuation of anti-CGRP mAbs resulted in progressive migraine deterioration that was rapidly reverted by retreatment. However, one-fourth of patients, who reported better quality of life indices before treatment, showed a sustained benefit during discontinuation and did not need retreatment.
-
Dr Hamid3yrImportant to fully evaluate migraine patients
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThese are a good way to know who may respond.
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35135357/
1 Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy. 2 Medical Toxicology-Headache and Drug Abuse Research Centre, Department of Biomedical, Metabolic and Neural Sciences, University...
Conclusion: Our results support the emerging evidence that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients irrespective of detoxification, yet further studies are needed to draw definitive conclusions.
-
Dr Hamid3yrMedication overuse headache significantly contributes to the chronification process and treatment refractoriness of migraine
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is important because taking patients off of abortives can be difficult.
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score - CNS Drugs
Source : https://link.springer.com/article/10.1007/s40263-021-00893-y
Background Criteria, including clinical features and effective outcomes, for access and persistence of novel but costly treatments may vary between countries, thus affecting the health of patients. Monoclonal antibodies against...
Conclusion: In resistant chronic migraine patients, anti-CGRP mAbs are effective and safe. A ≥ 50% reduction in MIDAS score seems to be the most advantageous outcome measure in this setting, which allows most severe migraine patients to persist with treatment.
-
Dr Hamid3yrIn resistant chronic migraine patients, anti-CGRP mAbs are effective
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThe MIDAS is a helpful score.
Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management
Source : https://www.sciencedirect.com/science/article/abs/pii/S0009308422000056?via=ihub
Glyceryl monostearate-based nanoparticles helped in the entrapment of drug in the lipophilic matrix system. * High-pressure homogenization used for preparation of Solid Lipid Nanoparticles (SLNs). * These SLNs via intranasal...
Conclusion/Relevance: Zolmitriptan-loaded SLNs via intranasal administration offers a novel approach to effectively circumvent first-pass hepatic metabolism than conventional oral route with 4-fold alleviation in permeation and 2-fold improvement in bioavailability.
Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
Source : https://www.frontiersin.org/articles/10.3389/fneur.2021.788159/full
Background: OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) target different migraine pathways, therefore, combination treatment may provide additional effectiveness for the preventive treatment of chronic migraine (CM) than...
Conclusion: In this real-world study, onabotulinumtoxinA was effective at reducing MHD and the addition of a CGRP mAb was safe, well-tolerated and associated with incremental and clinically meaningful reductions in MHD for those who stayed on the combination treatment. No new safety signals were identified. Of those who discontinued, the...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrStudies like these are so needed so insurances companies can start to cover these quickly.